SCHEMBL12900087

SCHEMBL12900087

O=C(Nc1ccccc1C(=O)O)c1cc(-c2ccc3ncccc3c2)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.52
▸ MAPK8 P45983 1/20 0.47
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ GSK3B P49841 1/20 0.45
▸ MEN1 O00255 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ POLB P06746 3/20 0.45
▸ RAB9A P51151 5/20 0.44
▸ NPC1 O15118 4/20 0.44
▸ TP53 P04637 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PABPC1 P11940 1/20 0.44
▸ GFER P55789 1/20 0.43
▸ DHODH Q02127 1/20 0.43
▸ PFKFB3 Q16875 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12900110 0.86 RAB9A (0.52) MEN1KMT2AALDH1A1POLBRAB9A
SCHEMBL12900086 0.78 HCAR2 (0.53) MCL1MAPK8MEN1KMT2AALDH1A1
SCHEMBL12900106 0.75 HSD17B1 (0.52) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL12900108 0.75 SERPINE1 (0.53) MCL1MEN1KMT2AALDH1A1POLB
SCHEMBL6451894 0.75 HCAR2 (0.52) MAPK8HDAC2MEN1KMT2AALDH1A1
SCHEMBL12900109 0.74 ALDH1A1 (0.49) MEN1KMT2AALDH1A1POLBRAB9A
SCHEMBL30838469 0.72 MCL1 (0.66) MCL1MAPK8GSK3BMEN1KMT2A
SCHEMBL420345 0.70 SERPINE1 (0.69) MCL1MEN1KMT2ARAB9ANPC1
SCHEMBL418849 0.69 SERPINE1 (0.67) MCL1MEN1KMT2ARAB9ANPC1
SCHEMBL12700385 0.69 NPC1 (0.74) MAPK8MEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2011-02-03 — — US disclosed
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2011-02-03 — — US disclosed
WO-2007035478-A2 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment LDLR, APOB, FFAR1 MCL1 4559/4885MAPK8 2419/4885HDAC1 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback